4//SEC Filing
Milla Marcos 4
Accession 0001209191-20-004925
CIK 0001609727other
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 6:31 PM ET
Size
13.0 KB
Accession
0001209191-20-004925
Insider Transaction Report
Form 4
Synthorx, Inc.THOR
Milla Marcos
Chief Scientific Officer
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2020-01-23$67.37/sh−89,237$6,011,897→ 0 totalExercise: $0.63Exp: 2027-07-31→ Common Stock (89,237 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-01-23$67.07/sh−227,806$15,278,948→ 0 totalExercise: $0.93Exp: 2028-05-16→ Common Stock (227,806 underlying) - Disposition from Tender
Common Stock
2020-01-23$68.00/sh−63,989$4,351,252→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2020-01-23$57.00/sh−125,000$7,125,000→ 0 totalExercise: $11.00Exp: 2028-12-05→ Common Stock (125,000 underlying)
Footnotes (3)
- [F1]This option, which provided for vesting of 25% of the shares one year after August 1, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $6,011,896.69, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
- [F2]This option, which provided for vesting of 25% of the shares one year after April 12, 2018, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $15,278,948.42, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
- [F3]This option, which provided for vesting of 33.333% of the shares on December 17, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $7,125,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Documents
Issuer
Synthorx, Inc.
CIK 0001609727
Entity typeother
Related Parties
1- filerCIK 0001760440
Filing Metadata
- Form type
- 4
- Filed
- Jan 23, 7:00 PM ET
- Accepted
- Jan 24, 6:31 PM ET
- Size
- 13.0 KB